获得性耐药-话题@MedSci

#获得性耐药#

9篇内容 | 709人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2185715, encodeId=554d2185e1586, content=<a href='/topic/show?id=51cbe247518' target=_blank style='color:#2F92EE;'>#直肠癌#</a> <a href='/topic/show?id=afa5965438d' target=_blank style='color:#2F92EE;'>#铁死亡#</a> <a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=Nat Cancer：南开大学陈佺等团队合作发现通过LGR4靶向激活结直肠癌铁死亡克服获得性耐药, objectType=article, longId=812120, objectId=2a2e81212027, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=2a2e81212027, replyNumber=0, likeNumber=30, createdTime=2024-02-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=2a2e81212027, moduleTitle=Nat Cancer：南开大学陈佺等团队合作发现通过LGR4靶向激活结直肠癌铁死亡克服获得性耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a2e81212027)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1967068, encodeId=a0eb196e0687d, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=NEJM：KRAS抑制剂获得性耐药机制研究, objectType=article, longId=213196, objectId=8eda2131962c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eda2131962c, replyNumber=0, likeNumber=47, createdTime=2022-04-14, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eda2131962c, moduleTitle=NEJM：KRAS抑制剂获得性耐药机制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eda2131962c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967067, encodeId=e60a196e067ba, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=Blood：与来那度胺/泊马度胺获得性耐药相关的多重CRBN变异！, objectType=article, longId=205835, objectId=b32b20583544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32b20583544, replyNumber=0, likeNumber=46, createdTime=2021-10-09, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32b20583544, moduleTitle=Blood：与来那度胺/泊马度胺获得性耐药相关的多重CRBN变异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b32b20583544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967066, encodeId=af87196e066fa, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异, objectType=article, longId=199253, objectId=e69319925396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69319925396, replyNumber=0, likeNumber=43, createdTime=2020-12-25, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69319925396, moduleTitle=Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69319925396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967065, encodeId=ed0d196e06543, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷, objectType=article, longId=121645, objectId=aec1121645ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aec1121645ac, replyNumber=0, likeNumber=31, createdTime=2018-10-30, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aec1121645ac, moduleTitle=CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aec1121645ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967064, encodeId=d43b196e06403, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, objectType=article, longId=115437, objectId=65d511543e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65d511543e88, replyNumber=0, likeNumber=33, createdTime=2018-06-30, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65d511543e88, moduleTitle=Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65d511543e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967063, encodeId=892f196e06339, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性, objectType=article, longId=99880, objectId=4d2e9988075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d2e9988075, replyNumber=0, likeNumber=44, createdTime=2017-06-10, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2e9988075, moduleTitle=CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d2e9988075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=研究发现肿瘤微环境导致获得性耐药新机制, objectType=article, longId=62456, objectId=492962456cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=492962456cc, replyNumber=0, likeNumber=34, createdTime=2016-01-24, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=492962456cc, moduleTitle=研究发现肿瘤微环境导致获得性耐药新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=492962456cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967061, encodeId=8368196e0616c, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, objectType=article, longId=35713, objectId=eb7735e1356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7735e1356, replyNumber=0, likeNumber=45, createdTime=2014-08-20, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7735e1356, moduleTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7735e1356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967060, encodeId=456e196e06043, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, objectTitle=Cancer Res.:揭示卵巢癌获得性耐药机制, objectType=article, longId=9091, objectId=0179909175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0179909175, replyNumber=0, likeNumber=39, createdTime=2012-09-01, rootId=0, userName=zhaozhouchifen, userId=524d95, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0179909175, moduleTitle=Cancer Res.:揭示卵巢癌获得性耐药机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0179909175)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

获得性耐药

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#直肠癌# #铁死亡# #获得性耐药#

Nat Cancer：南开大学陈佺等团队合作发现通过LGR4靶向激活结直肠癌铁死亡克服获得性耐药

2024-02-03发表于陕西省

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

NEJM：KRAS抑制剂获得性耐药机制研究

2022-04-14

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

Blood：与来那度胺/泊马度胺获得性耐药相关的多重CRBN变异！

2021-10-09

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异

2020-12-25

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷

2018-10-30

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药

2018-06-30

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性

2017-06-10

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

研究发现肿瘤微环境导致获得性耐药新机制

2016-01-24

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著

2014-08-20

zhaozhouchifen (审核中...)

前往app查看评论内容

#获得性耐药#

Cancer Res.:揭示卵巢癌获得性耐药机制

2012-09-01

科室
- - 订阅+
  - 更多科室
工具
服务